Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NYSE | Common Stock
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.
It serves general public, retail outlets, and distributors.
The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension.
This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use.
Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand.
This segment serves wholesalers, hospitals, and retailers.
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 17, 24 | 2.82 Increased by +0.71% | 2.70 Increased by +4.44% |
| Apr 16, 24 | 2.71 Increased by +1.12% | 2.64 Increased by +2.65% |
| Jan 23, 24 | 2.29 Decreased by -2.55% | 2.28 Increased by +0.44% |
| Oct 17, 23 | 2.66 Increased by +4.31% | 2.52 Increased by +5.56% |
| Jul 20, 23 | 2.80 Increased by +8.11% | 2.62 Increased by +6.87% |
| Apr 18, 23 | 2.68 Increased by +0.37% | 2.50 Increased by +7.20% |
| Jan 24, 23 | 2.35 Increased by +10.33% | 2.23 Increased by +5.38% |
| Oct 18, 22 | 2.55 Decreased by -1.92% | 2.47 Increased by +3.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 21.35 B Decreased by -10.26% | 26.03 B Increased by +483.85% | Increased by +121.91% Increased by +550.57% |
| Jun 30, 23 | 25.53 B Increased by +6.29% | 5.14 B Increased by +6.86% | Increased by +20.15% Increased by +0.53% |
| Mar 31, 23 | 24.75 B Increased by +5.63% | -68.00 M Decreased by -101.32% | Decreased by -0.27% Decreased by -101.25% |
| Dec 31, 22 | 23.71 B Decreased by -4.43% | 3.52 B Decreased by -25.68% | Increased by +14.85% Decreased by -22.23% |
| Sep 30, 22 | 23.79 B Increased by +1.94% | 4.46 B Increased by +21.57% | Increased by +18.74% Increased by +19.26% |
| Jun 30, 22 | 24.02 B Increased by +3.04% | 4.81 B Decreased by -23.32% | Increased by +20.04% Decreased by -25.58% |
| Mar 31, 22 | 23.43 B Increased by +4.95% | 5.15 B Decreased by -16.91% | Increased by +21.98% Decreased by -20.83% |
| Dec 31, 21 | 24.80 B Increased by +10.36% | 4.74 B Increased by +172.50% | Increased by +19.09% Increased by +146.91% |